Literature DB >> 27122861

Effects of Tissue-Type Plasminogen Site-Specific Transgene in Gelatin-Coated Dacron on the Fibrinolysis Activity of Rabbit Left Atrium.

Xiaobin Liu1, Kailun Zhang1, Xionggang Jiang1, Jiahong Xia1, Daokang Xiang2.   

Abstract

BACKGROUND: To investigate the effects of tissue-type plasminogen activator (tPA) gene transfer with left-atrium local positioning on the fibrinolytic activity of rabbit left atrial blood.
METHODS: A total of 48 rabbits were randomly divided into 3 groups (n = 16): gene therapy, vector control, and blank control groups. Each group was divided into 2 subgroups (8 rabbits in each subgroup) according to the sacrifice time on the postoperative 3(rd) and 14(th) days. The tPA mRNA transcriptional level and exogenous tPA protein expression within regional myocardial tissues of the left atrium were detected on the postoperative 3(rd) and 14(th) days. After excluding the animals that died, 6 samples of each subgroup were randomly selected for the statistics (n = 6).
RESULTS: The tPA activities in rabbit left atrial blood and peripheral blood were also detected. The tPAmRNA and tPA protein expressions within regional myocardial tissues were detected on the postoperative 3(rd) and 14(th) days. The tPA activity in left atrial blood in the gene therapy group was higher than the tPA activity of other groups (p < 0.02). No significant differences were observed in the tPA activity of peripheral blood among the 3 groups before surgery. A gelatin-coated Dacron piece, which carried the tPA gene, was implanted in the left atrial appendage.
CONCLUSIONS: The gelatin-coated Dacron piece could express and secrete tPA proteins in the region, thus enhancing the fibrinolytic activity of left atrial blood. KEY WORDS: Fibrinolytic activity; Gelatin coating; Gene; Left atrium; Tissue-type plasminogen activator.

Entities:  

Year:  2015        PMID: 27122861      PMCID: PMC4804880          DOI: 10.6515/acs20141114a

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  22 in total

1.  Oral anticoagulation and VKORC1 polymorphism in patients with a mechanical heart prosthesis: a 6-year follow-up.

Authors:  Carlo Giansante; Nicola Fiotti; Nicola Altamura; Paola Pitacco; Lara Consoloni; Sabino Scardi; Carmine Mazzone; Gabriele Grassi; Claudio Pandullo; Andrea Di Lenarda
Journal:  J Thromb Thrombolysis       Date:  2012-11       Impact factor: 2.300

2.  Controlled release of plasmid DNA from hydrogels prepared from gelatin cationized by different amine compounds.

Authors:  Toshihiro Kushibiki; Ryuji Tomoshige; Kazunori Iwanaga; Masawo Kakemi; Yasuhiko Tabata
Journal:  J Control Release       Date:  2006-03-20       Impact factor: 9.776

Review 3.  A new gene delivery system based on controlled release technology.

Authors:  Toshihiro Kushibiki; Yasuhiko Tabata
Journal:  Curr Drug Deliv       Date:  2004-04       Impact factor: 2.565

4.  Twenty years' single-center experience with mechanical heart valves: a critical review of anticoagulation policy.

Authors:  Guido J Van Nooten; Frank Caes; Katrien François; Yves Van Bellleghem; Thierry Bové; Guy Vandenplas; Yves Taeymans
Journal:  J Heart Valve Dis       Date:  2012-01

5.  Elevated intraluminal pressure inhibits vascular tissue plasminogen activator secretion and downregulates its gene expression.

Authors:  L S Sjögren; R Doroudi; L m Gan; L Jungersten; T Hrafnkelsdóttir; S Jern
Journal:  Hypertension       Date:  2000-04       Impact factor: 10.190

6.  Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B Investigators.

Authors:  C M Gibson; C P Cannon; S A Murphy; A A Adgey; M J Schweiger; R F Sequeira; G Grollier; N L Fox; S Berioli; W D Weaver; F Van de Werf; E Braunwald
Journal:  Am J Cardiol       Date:  1999-11-01       Impact factor: 2.778

7.  Adequate intensity of warfarin therapy for Korean patients with mechanical cardiac valves.

Authors:  In Kyung Yoon; Kyung Eun Lee; Jin Koo Lee; Byung Chul Chang; Hye Sun Gwak
Journal:  J Heart Valve Dis       Date:  2013-01

8.  Endograft technology: a delivery vehicle for intravascular gene therapy.

Authors:  Darwin Eton; Hong Yu; Yingcai Wang; Jeffrey Raines; Gary Striker; Alan Livingstone
Journal:  J Vasc Surg       Date:  2004-05       Impact factor: 4.268

9.  Low toxicity of cationic lipid-based emulsion for gene transfer.

Authors:  Woo-Jeong Choi; Jin-Ki Kim; Sung-Hee Choi; Jeong-Sook Park; Woong Shick Ahn; Chong-Kook Kim
Journal:  Biomaterials       Date:  2004-12       Impact factor: 12.479

10.  Gelatin nanospheres incorporating siRNA for controlled intracellular release.

Authors:  Hidefumi Ishikawa; Yoko Nakamura; Jun-ichiro Jo; Yasuhiko Tabata
Journal:  Biomaterials       Date:  2012-09-15       Impact factor: 12.479

View more
  1 in total

1.  Nanoparticle delivery of cardioprotective therapies.

Authors:  Abraham Mendez-Fernandez; Hector A Cabrera-Fuentes; Bhaarathy Velmurugan; Jason Irei; William A Boisvert; Shengjie Lu; Derek J Hausenloy
Journal:  Cond Med       Date:  2020-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.